1. Pneumomediastinum and pneumothorax in coronavirus disease-2019: Description of a case series and a matched cohort study
- Author
-
Aysun Tekin, Anusha Devarajan, Kenneth K. Sakata, Shahraz Qamar, Mayank Sharma, Diana J. Valencia Morales, Michael Malinchoc, Fahimeh Talaei, Stephanie Welle, Jamil Taji, Sandeep Khosa, Nikhil Sharma, Meghan Brown, Amos Lal, Vikas Bansal, Syed Anjum Khan, Abigail T. La Nou, Devang Sanghavi, Rodrigo Cartin-Ceba, Rahul Kashyap, Ognjen Gajic, Juan P. Domecq, and Natalya Azadeh
- Subjects
Coronavirus disease-2019 ,Pneumomediastinum ,Pneumothorax ,Respiratory support ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Objective: To describe the characteristics of COVID-19 patients with pneumothorax and pneumomediastinum (PTX/PM) and their association with patient outcomes. Patients and methods: Adults admitted to five Mayo Clinic hospitals with COVID-19 between 03/2020–01/2022 were evaluated. PTX/PM was defined by imaging. Descriptive analyses and a matched (age, sex, admission month, COVID-19 severity) cohort comparison was performed. Hospital mortality, length of stay (LOS), and predisposing factors were assessed. Results: Among 6663 patients, 197 had PTX/PM (3 %) (75 PM, 40 PTX, 82 both). The median age was 59, with 71 % males. Exposure to invasive and non-invasive mechanical ventilation and high-flow nasal cannula before PTX/PM were 42 %, 17 %, and 20 %, respectively. Among isolated PTX and PM/PTX patients 70 % and 53.7 % underwent an intervention, respectively, while 96 % of the PM-only group was followed conservatively.A total of 171 patients with PTX/PM were compared to 171 matched controls. PTX/PM patients had more underlying lung disease (40.9 vs. 23.4 %, p
- Published
- 2024
- Full Text
- View/download PDF